Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment

Mon S. Bryant, Diana H. Rintala, Jyhgong G. Hou, Ann L. Charness, Angel L. Fernandez, Robert L. Collins, Jeff Baker, Eugene C. Lai, Elizabeth J. Protas

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.

Original languageEnglish (US)
Pages (from-to)959-964
Number of pages6
JournalNeurological Research
Volume33
Issue number9
DOIs
StatePublished - Nov 2011

Fingerprint

Gait
Parkinson Disease
Levodopa
Walking Speed

Keywords

  • Gait variability
  • Levodopa
  • Parkinson's disease
  • Walking speed

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Bryant, M. S., Rintala, D. H., Hou, J. G., Charness, A. L., Fernandez, A. L., Collins, R. L., ... Protas, E. J. (2011). Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment. Neurological Research, 33(9), 959-964. https://doi.org/10.1179/1743132811Y.0000000044

Gait variability in Parkinson's disease : Influence of walking speed and dopaminergic treatment. / Bryant, Mon S.; Rintala, Diana H.; Hou, Jyhgong G.; Charness, Ann L.; Fernandez, Angel L.; Collins, Robert L.; Baker, Jeff; Lai, Eugene C.; Protas, Elizabeth J.

In: Neurological Research, Vol. 33, No. 9, 11.2011, p. 959-964.

Research output: Contribution to journalArticle

Bryant, MS, Rintala, DH, Hou, JG, Charness, AL, Fernandez, AL, Collins, RL, Baker, J, Lai, EC & Protas, EJ 2011, 'Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment', Neurological Research, vol. 33, no. 9, pp. 959-964. https://doi.org/10.1179/1743132811Y.0000000044
Bryant, Mon S. ; Rintala, Diana H. ; Hou, Jyhgong G. ; Charness, Ann L. ; Fernandez, Angel L. ; Collins, Robert L. ; Baker, Jeff ; Lai, Eugene C. ; Protas, Elizabeth J. / Gait variability in Parkinson's disease : Influence of walking speed and dopaminergic treatment. In: Neurological Research. 2011 ; Vol. 33, No. 9. pp. 959-964.
@article{190ba162e40c42839b895c8d13df43aa,
title = "Gait variability in Parkinson's disease: Influence of walking speed and dopaminergic treatment",
abstract = "Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.",
keywords = "Gait variability, Levodopa, Parkinson's disease, Walking speed",
author = "Bryant, {Mon S.} and Rintala, {Diana H.} and Hou, {Jyhgong G.} and Charness, {Ann L.} and Fernandez, {Angel L.} and Collins, {Robert L.} and Jeff Baker and Lai, {Eugene C.} and Protas, {Elizabeth J.}",
year = "2011",
month = "11",
doi = "10.1179/1743132811Y.0000000044",
language = "English (US)",
volume = "33",
pages = "959--964",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "9",

}

TY - JOUR

T1 - Gait variability in Parkinson's disease

T2 - Influence of walking speed and dopaminergic treatment

AU - Bryant, Mon S.

AU - Rintala, Diana H.

AU - Hou, Jyhgong G.

AU - Charness, Ann L.

AU - Fernandez, Angel L.

AU - Collins, Robert L.

AU - Baker, Jeff

AU - Lai, Eugene C.

AU - Protas, Elizabeth J.

PY - 2011/11

Y1 - 2011/11

N2 - Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.

AB - Objectives: To study the effects of levodopa and walking speed on gait variability in individuals with Parkinson's disease (PD). Methods: Thirty-three individuals with PD were studied. Their mean age was 70.61±9.23 year. The average time since diagnosis was 9.65±5.80 year. Gait variability was studied while 'OFF' and 'ON' dopaminergic medication when the subjects walked at their usual and fastest speeds. Results: Variability of step time, double support time, stride length and stride velocity decreased significantly (P=0.037; P=0.037; P=0.022; P=0.043, respectively) after dopaminergic treatment. When subjects increased walking speed, the variability of stride length and stride velocity decreased significantly (P=0.038 and P=0.004, respectively) both while 'OFF' and 'ON' levodopa. Increasing walking speed did not change the variability of step time and double support time regardless of medication status. Conclusions: Levodopa decreased gait variability in persons with PD. Stride length and stride velocity variability appeared to be speed dependent parameters, whereas, the variability of step time and double support time appeared to be speed independent measures. Levodopa had positive effects on gait stability in PD.

KW - Gait variability

KW - Levodopa

KW - Parkinson's disease

KW - Walking speed

UR - http://www.scopus.com/inward/record.url?scp=80855129489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855129489&partnerID=8YFLogxK

U2 - 10.1179/1743132811Y.0000000044

DO - 10.1179/1743132811Y.0000000044

M3 - Article

C2 - 22080998

AN - SCOPUS:80855129489

VL - 33

SP - 959

EP - 964

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 9

ER -